메뉴 건너뛰기




Volumn 46, Issue 3, 2015, Pages 783-794

Everolimus for the treatment of lymphangioleiomyomatosis: A phase II study

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; VASCULOTROPIN D; ANTINEOPLASTIC AGENT;

EID: 84942790944     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00210714     Document Type: Article
Times cited : (83)

References (46)
  • 1
    • 0032954005 scopus 로고    scopus 로고
    • Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis
    • Chu SC, Horiba K, Usuki J, et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115: 1041-1052.
    • (1999) Chest , vol.115 , pp. 1041-1052
    • Chu, S.C.1    Horiba, K.2    Usuki, J.3
  • 2
    • 0032798054 scopus 로고    scopus 로고
    • Decline in lung function in lymphangioleiomyomatosis: Relation to menopause and progesterone treatment
    • Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160: 628-633.
    • (1999) Am J Respir Crit Care Med , vol.160 , pp. 628-633
    • Johnson, S.R.1    Tattersfield, A.E.2
  • 3
    • 0032822920 scopus 로고    scopus 로고
    • Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de recherche sur les maladies "Orphelines" pulmonaires (GERM"O"P)
    • Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 1999; 78: 321-337.
    • (1999) Medicine (Baltimore) , vol.78 , pp. 321-337
    • Urban, T.1    Lazor, R.2    Lacronique, J.3
  • 4
    • 0033671345 scopus 로고    scopus 로고
    • Clinical experience of lymphangioleiomyomatosis in the UK
    • Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000; 55: 1052-1057.
    • (2000) Thorax , vol.55 , pp. 1052-1057
    • Johnson, S.R.1    Tattersfield, A.E.2
  • 5
    • 10444277302 scopus 로고    scopus 로고
    • Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone
    • Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126: 1867-1874.
    • (2004) Chest , vol.126 , pp. 1867-1874
    • Taveira-DaSilva, A.M.1    Stylianou, M.P.2    Hedin, C.J.3
  • 6
    • 30344457333 scopus 로고    scopus 로고
    • The NHLBI lymphangioleiomyomatosis registry: Characteristics of 230 patients at enrollment
    • Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173: 105-111.
    • (2006) Am J Respir Crit Care Med , vol.173 , pp. 105-111
    • Ryu, J.H.1    Moss, J.2    Beck, G.J.3
  • 7
    • 0034082444 scopus 로고    scopus 로고
    • High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex
    • Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000; 75: 591-594.
    • (2000) Mayo Clin Proc , vol.75 , pp. 591-594
    • Costello, L.C.1    Hartman, T.E.2    Ryu, J.H.3
  • 9
    • 0025011582 scopus 로고
    • Lymphangioleiomyomatosis. Clinical course in 32 patients
    • Taylor JR, Ryu J, Colby TV, et al. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990; 323: 1254-1260.
    • (1990) N Engl J Med , vol.323 , pp. 1254-1260
    • Taylor, J.R.1    Ryu, J.2    Colby, T.V.3
  • 10
    • 34447261147 scopus 로고    scopus 로고
    • Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex
    • Schiavina M, Di Scioscio V, Contini P, et al. Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. Am J Respir Crit Care Med 2007; 176: 96-98.
    • (2007) Am J Respir Crit Care Med , vol.176 , pp. 96-98
    • Schiavina, M.1    Di Scioscio, V.2    Contini, P.3
  • 11
    • 0034705207 scopus 로고    scopus 로고
    • Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis
    • Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000; 97: 6085-6090.
    • (2000) Proc Natl Acad Sci USA , vol.97 , pp. 6085-6090
    • Carsillo, T.1    Astrinidis, A.2    Henske, E.P.3
  • 13
    • 77953005726 scopus 로고    scopus 로고
    • Lymphangioleiomyomatosis (LAM): Molecular insights lead to targeted therapies
    • Glasgow CG, Steagall WK, Taveira-Dasilva A, et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 2010; 104: Suppl. 1, S45-S58.
    • (2010) Respir Med , vol.104 , pp. S45-S58
    • Glasgow, C.G.1    Steagall, W.K.2    Taveira-Dasilva, A.3
  • 14
    • 65949104047 scopus 로고    scopus 로고
    • Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement
    • Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009; 135: 1293-1300.
    • (2009) Chest , vol.135 , pp. 1293-1300
    • Glasgow, C.G.1    Avila, N.A.2    Lin, J.P.3
  • 15
    • 33846073861 scopus 로고    scopus 로고
    • Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis
    • Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006; 4: 143-152.
    • (2006) Lymphat Res Biol , vol.4 , pp. 143-152
    • Seyama, K.1    Kumasaka, T.2    Souma, S.3
  • 16
    • 77956799312 scopus 로고    scopus 로고
    • Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases
    • Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010; 138: 674-681.
    • (2010) Chest , vol.138 , pp. 674-681
    • Young, L.R.1    Vandyke, R.2    Gulleman, P.M.3
  • 17
    • 84881343915 scopus 로고    scopus 로고
    • Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: A prospective analysis of the multicenter international lymphangioleiomyomatosis efficacy of sirolimus (MILES) trial
    • Young LR, Lee HS, Inoue Y, et al. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013; 1: 445-452.
    • (2013) Lancet Respir Med , vol.1 , pp. 445-452
    • Young, L.R.1    Lee, H.S.2    Inoue, Y.3
  • 19
    • 39449100827 scopus 로고    scopus 로고
    • Lymphangioleiomyomatosis: A clinical update
    • McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest 2008; 133: 507-516.
    • (2008) Chest , vol.133 , pp. 507-516
    • McCormack, F.X.1
  • 20
    • 4544315390 scopus 로고    scopus 로고
    • Survival and disease progression in UK patients with lymphangioleiomyomatosis
    • Johnson SR, Whale CI, Hubbard RB, et al. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004; 59: 800-803.
    • (2004) Thorax , vol.59 , pp. 800-803
    • Johnson, S.R.1    Whale, C.I.2    Hubbard, R.B.3
  • 21
    • 2542551101 scopus 로고    scopus 로고
    • Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis
    • Lazor R, Valeyre D, Lacronique J, et al. Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir Med 2004; 98: 536-541.
    • (2004) Respir Med , vol.98 , pp. 536-541
    • Lazor, R.1    Valeyre, D.2    Lacronique, J.3
  • 22
    • 12144249965 scopus 로고    scopus 로고
    • Decline in lung function in the busselton health study: The effects of asthma and cigarette smoking
    • James AL, Palmer LJ, Kicic E, et al. Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 2005; 171: 109-114.
    • (2005) Am J Respir Crit Care Med , vol.171 , pp. 109-114
    • James, A.L.1    Palmer, L.J.2    Kicic, E.3
  • 23
    • 84895437651 scopus 로고    scopus 로고
    • A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis
    • Chang WY, Cane JL, Kumaran M, et al. A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J 2014; 43: 1114-1123.
    • (2014) Eur Respir J , vol.43 , pp. 1114-1123
    • Chang, W.Y.1    Cane, J.L.2    Kumaran, M.3
  • 24
    • 39449120136 scopus 로고    scopus 로고
    • Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis
    • Harari S, Cassandro R, Chiodini I, et al. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest 2008; 133: 448-454.
    • (2008) Chest , vol.133 , pp. 448-454
    • Harari, S.1    Cassandro, R.2    Chiodini, I.3
  • 25
    • 79955510505 scopus 로고    scopus 로고
    • Efficacy and safety of sirolimus in lymphangioleiomyomatosis
    • McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-1606.
    • (2011) N Engl J Med , vol.364 , pp. 1595-1606
    • McCormack, F.X.1    Inoue, Y.2    Moss, J.3
  • 26
    • 38049169559 scopus 로고    scopus 로고
    • Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis
    • Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
    • (2008) N Engl J Med , vol.358 , pp. 140-151
    • Bissler, J.J.1    McCormack, F.X.2    Young, L.R.3
  • 27
    • 38049177875 scopus 로고    scopus 로고
    • Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis
    • Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008; 358: 200-203.
    • (2008) N Engl J Med , vol.358 , pp. 200-203
    • Davies, D.M.1    Johnson, S.R.2    Tattersfield, A.E.3
  • 28
    • 84874746597 scopus 로고    scopus 로고
    • Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial
    • Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817-824.
    • (2013) Lancet , vol.381 , pp. 817-824
    • Bissler, J.J.1    Kingswood, J.C.2    Radzikowska, E.3
  • 30
    • 20144382361 scopus 로고    scopus 로고
    • Minimal clinically important differences in COPD lung function
    • Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005; 2: 111-124.
    • (2005) COPD , vol.2 , pp. 111-124
    • Donohue, J.F.1
  • 31
    • 43249086546 scopus 로고    scopus 로고
    • Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    • O'Donnell A, Faivre S, Burris HAIII, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588-1595.
    • (2008) J Clin Oncol , vol.26 , pp. 1588-1595
    • O'Donnell, A.1    Faivre, S.2    Burris, H.A.3
  • 32
    • 84897056068 scopus 로고    scopus 로고
    • Adverse event management in patients with advanced cancer receiving oral everolimus: Focus on breast cancer
    • Aapro M, Andre F, Blackwell K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Nutr Metab 2014; 25: 763-773.
    • (2014) Ann Nutr Metab , vol.25 , pp. 763-773
    • Aapro, M.1    Andre, F.2    Blackwell, K.3
  • 33
    • 84919906810 scopus 로고    scopus 로고
    • A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients
    • Yao J, Wang JY, Liu Y, et al. A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients. Med Oncol 2014; 31: 251-256.
    • (2014) Med Oncol , vol.31 , pp. 251-256
    • Yao, J.1    Wang, J.Y.2    Liu, Y.3
  • 34
    • 84889008307 scopus 로고    scopus 로고
    • Safety and efficacy of everolimus with exemestane vs exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
    • Pritchard KI, Burris HAIII, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013; 13: 421-432.
    • (2013) Clin Breast Cancer , vol.13 , pp. 421-432
    • Pritchard, K.I.1    Burris, H.A.2    Ito, Y.3
  • 35
    • 77956227464 scopus 로고    scopus 로고
    • Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors
    • Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265.
    • (2010) Cancer , vol.116 , pp. 4256-4265
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 36
    • 78049510428 scopus 로고    scopus 로고
    • Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis
    • Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363: 1801-1811.
    • (2010) N Engl J Med , vol.363 , pp. 1801-1811
    • Krueger, D.A.1    Care, M.M.2    Holland, K.3
  • 37
    • 84873653141 scopus 로고    scopus 로고
    • Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma
    • Krueger DA, Care MM, Agricola K, et al. Everolimus long-term safety and efficacy in subependymal giant-cell astrocytoma. Neurology 2013; 80: 574-580.
    • (2013) Neurology , vol.80 , pp. 574-580
    • Krueger, D.A.1    Care, M.M.2    Agricola, K.3
  • 38
    • 84872088946 scopus 로고    scopus 로고
    • Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial
    • Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381: 125-132.
    • (2013) Lancet , vol.381 , pp. 125-132
    • Franz, D.N.1    Belousova, E.2    Sparagana, S.3
  • 39
    • 84925231101 scopus 로고    scopus 로고
    • Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
    • Franz DN, Belousova E, Sparagana S, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 2014; 15: 1513-1520.
    • (2014) Lancet Oncol , vol.15 , pp. 1513-1520
    • Franz, D.N.1    Belousova, E.2    Sparagana, S.3
  • 40
    • 79959639375 scopus 로고    scopus 로고
    • Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus
    • Taveira-DaSilva AM, Hathaway O, Stylianou M, et al. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154: 797-805.
    • (2011) Ann Intern Med , vol.154 , pp. 797-805
    • Taveira-DaSilva, A.M.1    Hathaway, O.2    Stylianou, M.3
  • 41
    • 84916226614 scopus 로고    scopus 로고
    • Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis
    • Yao J, Taveira-DaSilva AM, Jones AM, et al. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2014; 190: 1273-1282.
    • (2014) Am J Respir Crit Care Med , vol.190 , pp. 1273-1282
    • Yao, J.1    Taveira-DaSilva, A.M.2    Jones, A.M.3
  • 42
    • 84882833554 scopus 로고    scopus 로고
    • The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis
    • Ando K, Kurihara M, Kataoka H, et al. The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Invest 2013; 51: 175-183.
    • (2013) Respir Invest , vol.51 , pp. 175-183
    • Ando, K.1    Kurihara, M.2    Kataoka, H.3
  • 43
    • 79959262531 scopus 로고    scopus 로고
    • Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: A phase 2 trial
    • Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011; 17: 4071-4081.
    • (2011) Clin Cancer Res , vol.17 , pp. 4071-4081
    • Davies, D.M.1    De Vries, P.J.2    Johnson, S.R.3
  • 45
    • 17144373720 scopus 로고    scopus 로고
    • Inhibitors of the mammalian target of rapamycin
    • Dancey JE. Inhibitors of the mammalian target of rapamycin. Exp Opin Invest Drugs 2005; 14: 313-328.
    • (2005) Exp Opin Invest Drugs , vol.14 , pp. 313-328
    • Dancey, J.E.1
  • 46
    • 84919360810 scopus 로고    scopus 로고
    • Chronic sirolimus therapy for lymphangioleiomyomatosis
    • McCormack FX. Chronic sirolimus therapy for lymphangioleiomyomatosis. Am J Respir Crit Care Med 2014; 190: 1332-1333.
    • (2014) Am J Respir Crit Care Med , vol.190 , pp. 1332-1333
    • McCormack, F.X.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.